Johnson & Johnson (JNJ)

$241.31 +0.01 (0.00%)
Market Cap 574.24B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 22.08
Forward PE 20.66
Profit Margin 28.46%
Debt to Equity Ratio 0.48
Volume 6,216,400
Avg Vol 8,443,632
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 56%
Beta 0.34
Analysts Strong Sell
Price Target $243.16

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
DragonAlgo
DragonAlgo Apr. 10 at 12:22 AM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-17 | Strike: $242.50 | Type: CALL Option Plan (premium): Entry: $4.30 Stop: $3.10 TP1: $5.59 TP2: $7.31 TP3: $10.32 🔗 https://dragonalgo.com
0 · Reply
snowPOW
snowPOW Apr. 9 at 9:03 PM
$BB Good to find out Johnson & Johnson $JNJ using QNX from BlackBerry in their heart equipment on the blowout beat earnings call this morning. QNX is expanding in medical equipment IoT for good reasons. $SIEMENS.NSE Yeah! THAT BlackBerry.
0 · Reply
EthelBurkhardt272
EthelBurkhardt272 Apr. 9 at 7:10 PM
$JNJ $UNH not loud, just consistently supported… that’s real demand
0 · Reply
Pearl_Power
Pearl_Power Apr. 9 at 6:13 PM
$JNJ setting up into earnings
0 · Reply
RyaKelly
RyaKelly Apr. 9 at 5:41 PM
$JNJ quiet strength is still strength
0 · Reply
trenddetector
trenddetector Apr. 9 at 5:15 PM
$JNJ Your Cancer Path url and beta is now live! www.yourcancerpath.com
0 · Reply
Wallst45
Wallst45 Apr. 9 at 3:27 PM
$JNJ $MDGL good choice
0 · Reply
NasdaqPulse
NasdaqPulse Apr. 9 at 2:46 PM
Market Watch - Key Moves Today 👉Click to view @NasdaqPulse for timely updates amid the volatility. $AAPL showing some serious weakness today, down -0.58% and -0.63%. Looks like selling pressure is building. On the flip side, $JNJ is holding strong with a +0.42% gain. This one's showing resilience despite the broader market mood. The macro context is heavy right now — delays in big tech projects and broader sentiment issues are dragging things down. It's clear investors are cautious, especially in the tech space. Keep an eye on $AAPL for further signs of weakness, while $JNJ might continue to outperform in the current environment.
0 · Reply
1986iamwallstreet
1986iamwallstreet Apr. 9 at 2:34 PM
$JNJ go ahead and make the purchase of $MDGL for 20 billion
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 9 at 1:13 PM
Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value $NGTF $NVDA $JNJ $AMZN $TSLA https://ibn.fm/16tH7
0 · Reply
Latest News on JNJ
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Apr 9, 2026, 7:57 AM EDT - 16 hours ago

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Apr 8, 2026, 10:41 AM EDT - 1 day ago

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Apr 7, 2026, 8:00 AM EDT - 2 days ago

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Royalty Pharma and J&J partner to develop autoimmune treatment

Mar 30, 2026, 9:14 AM EDT - 10 days ago

Royalty Pharma and J&J partner to develop autoimmune treatment

RPRX

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Mar 28, 2026, 10:00 AM EDT - 12 days ago

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Mar 27, 2026, 4:46 PM EDT - 13 days ago

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Mar 27, 2026, 6:31 AM EDT - 13 days ago

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

The Big 3: ORCL, JNJ, SBUX

Mar 19, 2026, 1:00 PM EDT - 21 days ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

Mar 19, 2026, 9:35 AM EDT - 21 days ago

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 22 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK LLY

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Mar 18, 2026, 1:17 PM EDT - 22 days ago

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 8:31 AM EDT - 22 days ago

US FDA approves J&J's oral psoriasis pill

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Mar 18, 2026, 7:49 AM EDT - 22 days ago

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Mar 16, 2026, 11:00 AM EDT - 24 days ago

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Mar 13, 2026, 12:35 PM EDT - 27 days ago

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Mar 12, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 3:55 PM EST - 5 weeks ago

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

US FDA approves JNJ's blood cancer drug

Mar 5, 2026, 2:21 PM EST - 5 weeks ago

US FDA approves JNJ's blood cancer drug

Johnson & Johnson launches website for direct-to-consumer sales

Mar 4, 2026, 6:07 PM EST - 5 weeks ago

Johnson & Johnson launches website for direct-to-consumer sales

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Mar 3, 2026, 8:03 AM EST - 5 weeks ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Mar 2, 2026, 4:30 PM EST - 5 weeks ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 26, 2026, 2:30 PM EST - 6 weeks ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 24, 2026, 4:03 PM EST - 6 weeks ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 11:35 AM EST - 6 weeks ago

Does JNJ Stock Still Offer Value?

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:43 AM EST - 6 weeks ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 23, 2026, 10:28 AM EST - 6 weeks ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 21, 2026, 8:00 AM EST - 6 weeks ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Feb 19, 2026, 5:00 PM EST - 7 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Feb 19, 2026, 2:34 PM EST - 7 weeks ago

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Feb 19, 2026, 2:11 PM EST - 7 weeks ago

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

Feb 18, 2026, 10:44 AM EST - 7 weeks ago

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Feb 18, 2026, 10:17 AM EST - 7 weeks ago

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Feb 18, 2026, 10:15 AM EST - 7 weeks ago

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Feb 18, 2026, 7:30 AM EST - 7 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Feb 17, 2026, 8:00 AM EST - 7 weeks ago

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Feb 13, 2026, 4:19 PM EST - 7 weeks ago

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Feb 13, 2026, 4:18 PM EST - 7 weeks ago

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial

Feb 13, 2026, 2:43 PM EST - 7 weeks ago

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial

After A 55% Surge, Is JNJ Stock Still A Buy?

Feb 13, 2026, 7:00 AM EST - 7 weeks ago

After A 55% Surge, Is JNJ Stock Still A Buy?

NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review

Feb 11, 2026, 2:23 PM EST - 2 months ago

NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

Feb 9, 2026, 4:16 PM EST - 2 months ago

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Feb 6, 2026, 7:00 PM EST - 2 months ago

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

The Big 3: JNJ, XOM, KO

Feb 5, 2026, 1:00 PM EST - 2 months ago

The Big 3: JNJ, XOM, KO

XOM KO

These hot S&P 500 stocks show where investors are heading as they run away from tech

Feb 4, 2026, 1:37 PM EST - 2 months ago

These hot S&P 500 stocks show where investors are heading as they run away from tech

FDX NOC NSC RTX WMT XOM

What's Behind The 50% Surge In JNJ Stock?

Feb 3, 2026, 8:47 AM EST - 2 months ago

What's Behind The 50% Surge In JNJ Stock?

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland

Feb 3, 2026, 3:00 AM EST - 2 months ago

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 2, 2026, 4:34 PM EST - 2 months ago

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

Jan 30, 2026, 7:19 AM EST - 2 months ago

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy

Jan 29, 2026, 6:32 PM EST - 2 months ago

US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy

This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks

Jan 29, 2026, 12:42 PM EST - 2 months ago

This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks

LOW

DragonAlgo
DragonAlgo Apr. 10 at 12:22 AM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-17 | Strike: $242.50 | Type: CALL Option Plan (premium): Entry: $4.30 Stop: $3.10 TP1: $5.59 TP2: $7.31 TP3: $10.32 🔗 https://dragonalgo.com
0 · Reply
snowPOW
snowPOW Apr. 9 at 9:03 PM
$BB Good to find out Johnson & Johnson $JNJ using QNX from BlackBerry in their heart equipment on the blowout beat earnings call this morning. QNX is expanding in medical equipment IoT for good reasons. $SIEMENS.NSE Yeah! THAT BlackBerry.
0 · Reply
EthelBurkhardt272
EthelBurkhardt272 Apr. 9 at 7:10 PM
$JNJ $UNH not loud, just consistently supported… that’s real demand
0 · Reply
Pearl_Power
Pearl_Power Apr. 9 at 6:13 PM
$JNJ setting up into earnings
0 · Reply
RyaKelly
RyaKelly Apr. 9 at 5:41 PM
$JNJ quiet strength is still strength
0 · Reply
trenddetector
trenddetector Apr. 9 at 5:15 PM
$JNJ Your Cancer Path url and beta is now live! www.yourcancerpath.com
0 · Reply
Wallst45
Wallst45 Apr. 9 at 3:27 PM
$JNJ $MDGL good choice
0 · Reply
NasdaqPulse
NasdaqPulse Apr. 9 at 2:46 PM
Market Watch - Key Moves Today 👉Click to view @NasdaqPulse for timely updates amid the volatility. $AAPL showing some serious weakness today, down -0.58% and -0.63%. Looks like selling pressure is building. On the flip side, $JNJ is holding strong with a +0.42% gain. This one's showing resilience despite the broader market mood. The macro context is heavy right now — delays in big tech projects and broader sentiment issues are dragging things down. It's clear investors are cautious, especially in the tech space. Keep an eye on $AAPL for further signs of weakness, while $JNJ might continue to outperform in the current environment.
0 · Reply
1986iamwallstreet
1986iamwallstreet Apr. 9 at 2:34 PM
$JNJ go ahead and make the purchase of $MDGL for 20 billion
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 9 at 1:13 PM
Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value $NGTF $NVDA $JNJ $AMZN $TSLA https://ibn.fm/16tH7
0 · Reply
sblack9k
sblack9k Apr. 9 at 12:13 PM
$BB $JNJ
0 · Reply
EthelBurkhardt272
EthelBurkhardt272 Apr. 9 at 12:12 PM
$JNJ not exciting, just reliable - and that’s enough
0 · Reply
frb1985
frb1985 Apr. 9 at 10:58 AM
$JNJ wait. What. LOL
0 · Reply
frb1985
frb1985 Apr. 9 at 10:57 AM
$JNJ wait what. LOL
0 · Reply
DragonAlgo
DragonAlgo Apr. 9 at 7:43 AM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-10 | Strike: $242.50 | Type: CALL Option Plan (premium): Entry: $1.13 Stop: $0.81 TP1: $1.47 TP2: $1.92 TP3: $2.71 Momentum tape remains active. 🔗 https://dragonalgo.com
0 · Reply
profitscout8
profitscout8 Apr. 9 at 7:41 AM
$JNJ The breakup with Kenvue has made J&J a pure-play pharma and med-tech powerhouse. The legal overhangs are finally being settled. It's a AAA-rated balance sheet—one of the few left in the world. I love the stability here. The dividend increase streak is legendary. This is a cornerstone of my portfolio for a reason. Buying the consolidation.
0 · Reply
SenefAS
SenefAS Apr. 9 at 7:22 AM
$GMAB Genmab is still undervalued a this level… $NVO $JNJ $PFE
0 · Reply
The__short_squeezer
The__short_squeezer Apr. 8 at 9:03 PM
$WMT $ORCL $MU $SNDK $JNJ I was partially right. Even though the regime has not fallen (but I believe it will eventually fall through a civilian process), Trump and certainly Netanyahu will not do this stupid thing of continuing the war for the long term. Now is the time for the market to calm down and reach new heights. Trump and Netanyahu have proven that they are responsible leaders!
3 · Reply
TechTraderGrok
TechTraderGrok Apr. 8 at 8:19 PM
Bought $JNJ at $240.84. From Grok: "JNJ looks attractive for a long here with bullish analyst notes targeting $250, solid pipeline momentum, and constructive longer-term uptrend ahead of earnings. " https://www.techtrader.ai/grokwall/?post=17637&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
trenddetector
trenddetector Apr. 8 at 6:37 PM
$JNJ Made some updates here. Please share with those in need! "Your path through cancer's complexity. Explore every approved treatment, every open clinical trial, and every option your doctor might not know to mention — all in plain English, all in one place. Browse anonymously. No account required.” https://nimble-frangollo-81ff5e.netlify.app/#
0 · Reply
IN0V8
IN0V8 Apr. 8 at 2:55 PM
$JNJ Opportunity Citigroup raises target price to $285 from $274
0 · Reply
DragonAlgo
DragonAlgo Apr. 8 at 2:04 PM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-10 | Strike: $260.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 🔗 https://dragonalgo.com
0 · Reply